Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus Octreotide in Advanced Carcinoid Tumor
NCT00412061Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2006
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in Carcinoid Tumor (CT) comparing Octreotide+ Everolimus with Octreotide+ Placebo (2 arms). Primary endpoint: Progression Free Survival. Started Dec 2006; status: completed.
02
Drugs
everolimus
03
Conditions
Carcinoid Tumor (CT)
Beyond the preview
Go deeper on NCT00412061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00412061.